Jyong Biotech Ltd. (MENS) is in Healthcare, Biotechnology, based in Taiwan, listed on NasdaqGM. Market cap 159.66M USD. 52-week range 1.43 to 63.00 USD. Data as of 2026-10-09.
Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome. The company was founded in 2002 and is headquartered in ...